Immunotherapies, cancer vaccines and more from Cancer Today’s coverage of the AACR Annual Meeting 2025.

As people with advanced disease live longer, they face physical and mental health side effects. Patient advocates say research and care must focus on their unique needs.

by Thomas Celona

Scientists present data on the risks of immune checkpoint inhibitors so more patients can tap into the treatment.

by Marci A. Landsmann

Tailored treatments led to better outcomes than standard of care when biomarker results from liquid biopsy and tumor tissue aligned.

by Eric Fitzsimmons

While mRNA vaccines offer a personalized approach to triggering an immune response, peptide vaccines could be a one-size-fits-all treatment. Researchers are exploring both options.

by Thomas Celona

U.S. breast cancer deaths declined for women ages 20 to 49, which researchers credit to wider screening and better treatment.

by Kevin McLaughlin

Women were more likely than men to have fatigue or depression linked to cancer, and both effects were linked to people withdrawing from physical activities.

by Eric Fitzsimmons

Combining an immune checkpoint inhibitor with standard care extended event-free survival by nearly two years.

by Thomas Celona

Scientists and former administrators gather for session focused on advocating for cancer research in uncertain times.

by Kevin McLaughlin

Immunotherapy can induce a complete response in some people with mismatch repair-deficient cancers with solid tumors.

by Thomas Celona